Daiichi Sankyo has submitted a new drug application for edoxaban in Japan.

Used in the treatment of venous thromboembolism (VTE) following orthopedic surgeries, edoxaban is an oral anticoagulant that directly inhibits factor Xa, which is responsible for blood clots.

Pivotal phase 3 studies indicate that oral administration of edoxaban once a day reduced the incidence of VTE in patients undergoing total knee or hip replacement.

The global clinical development programme for edoxaban aims at the prevention of stroke and systemic embolic events in patients with atrial fibrillation as well as long-term secondary prevention of VTE.